AI's Drug Resurrection Play: Hunting Pharma's Abandoned Pipeline
Key points
Key takeaways from Tank Talks interview with Biossil co-founder and CEO Anthony Mouchantaf (September 2026):
The graveyard thesis. The next breakthrough medicine may already exist, abandoned among pharma's shelved candidates — drugs worth billions that original sponsors could no longer afford to advance. Biossil applies AI to resurrect them at industrial scale, aiming to build Canada's first homegrown large-scale biotech company.
How the model works. Biossil buys or licenses late-stage assets whose safety profile is already well understood — often dosed in hundreds of patients — then matches each molecule to the patient subpopulation most likely to respond using multimodal AI, taking asymmetric risk on de-risked assets rather than designing new chemistry.
Pipeline and partnerships. The company today holds 11 distinct molecules and five open clinical trials across the US, Canada and Europe, partnering with research hospitals such as the University of California, Boston Children's and MD Anderson. The core team is roughly eight people, plus an extended team north of 30 supporting individual drug programs.
An operating hedge fund. Mouchantaf frames Biossil's model around alpha and beta. Alpha comes from being best-in-world at execution; beta is hedged through a resilient balance sheet, catalyst density and repricing opportunities across a portfolio of trials and disease areas, so binary clinical risk is normalised across many readouts rather than concentrated on one.
Why OpenAI and Founders Fund. The investors' balance sheet let Biossil acquire and advance assets years earlier than planned. Mouchantaf argues AI labs lean into biology because health and longevity are AI's most tangible, welcome upside. For Biossil, AI's leverage is not in new chemistry but in understanding the full clinical context of known drugs — semantic information — which is where model capability comes in.
Regulation is the bottleneck. Discovery is not the constraint: the journey from molecule to market is immensely laborious, and AI cannot yet substitute clinical evidence. He calls for deep regulatory reform, treating safety and efficacy as non-binary continua, and returning sovereignty to patients, caregivers and physicians once risks are well understood.
Founder journey. From law school without ever practicing, to co-founding Rhythm with Alex Mosa, through investor roles at OMERS Ventures in London and building up the RBCx group at RBC, and back into the founder seat with his old co-founder. He argues great VCs bring conviction plus a probabilistic mindset, while mediocre VCs cluster around cognitive shortcuts.
Ten-year mission. Approved drugs, a deeper pipeline, more trials across further disease areas and first-to-market mechanisms of action — perfecting the industrial system of not letting drugs fall by the wayside. His founder advice: entrepreneurship is brutally hard, so pursue it only when you are passionate about a specific problem, not for its own sake.
Read more: YouTube — Tank Talks by Ripple Ventures · Tank Talks
